BDRX Stock: Biodexa Pharmaceuticals Plc Stock Price, Analysis & Insights
Get live bdrx stock price $6.54, comprehensive Biodexa Pharmaceuticals Plc stock analysis, charts, news, and expert forecast. Real-time bdrx stock data and investment insights.
Loading chart...
Company Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Company Information
- CEO
- Stephen Anthony Stamp
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
Contact Information
- Address
- 1 Caspian Point
- Country
- GB
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Biodexa Pharmaceuticals Plc operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Stephen Anthony Stamp, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Biodexa Pharmaceuticals Plc competes in the Biotechnology within the broader Healthcare. With 4.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Biodexa Pharmaceuticals Plc provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Biodexa Pharmaceuticals Plc should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Biodexa Pharmaceuticals Plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Biodexa Pharmaceuticals Plc
- ⚠Investors should consider how Biodexa Pharmaceuticals Plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
4.05M
P/E Ratio
-0.25
Beta
0.96
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 4.05M market capitalization
- Trading Volume: 503.44K shares traded today
- Price Range: 52-week range of $3.58 - $92.00
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc (BDRX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 4.05M, the company represents a significant player in its market. The stock is currently trading at $6.54 with a negativedaily change of 2.66%.
The company's 13 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.25, beta of 0.96, and 52-week price range from $3.58 to $92.00when evaluating investment opportunities.
Why Invest in Biodexa Pharmaceuticals Plc?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Stephen Anthony Stamp
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.